INFUHealthcare · Medical DevicesThe 4 Wall Street analysts covering InfuSystem Holdings, Inc. hold a median 12-month price target of $15 — +62.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores InfuSystem Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (99): The share count has been shrinking and the company is not leaning on new borrowing.
Volatility (45): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own InfuSystem Holdings, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on INFU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +62.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Feb 2026 | Roth Capital | Reiterates | Buy | — |
| 5 Nov 2025 | Roth Capital | Reiterates | Buy | — |
| 22 July 2025 | Roth Capital | Initiates | Buy | — |
| 26 Sept 2024 | B. Riley Securities | Initiates | Buy | — |
| 26 Apr 2021 | Northland Capital Markets | Initiates | Outperform | — |
| 31 Aug 2020 | Craig-Hallum | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 32% of US stocks
Cheaper than 64% of US stocks
Cheaper than 32% of US stocks
Cheaper than 44% of US stocks
Higher than 24% of US stocks
Higher than 33% of US stocks
Higher than 73% of US stocks
Higher than 57% of US stocks
Higher than 61% of US stocks
Higher than 73% of US stocks
Higher than 84% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INFU appears on the weeks it earns a place.
InfuSystem announced it will report its second quarter 2026 financial results on August 4, 2026, according to a Business Wire release.
Why it matters — The earnings release date gives INFU watchers a specific date to look forward to for the company's quarterly financial update.
The 4 Wall Street analysts covering InfuSystem Holdings, Inc. have a median 12-month price target of $15, with estimates ranging from $12 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering InfuSystem Holdings, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InfuSystem Holdings, Inc. 100 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, InfuSystem Holdings, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (99 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +62.7% from the last close, and Ticker Nerd's factor model ranks InfuSystem Holdings, Inc. 100 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering InfuSystem Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INFU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $18 over the next 12 months.
InfuSystem Holdings, Inc. returned +61.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
InfuSystem Holdings Inc. is a leading provider of healthcare services specializing in the supply of durable medical equipment and third-party billing services across the United States and Canada.
The most recent item we track (Business Wire, 28 July 2026): "InfuSystem to Report Second Quarter 2026 Financial Results on August 4, 2026". InfuSystem announced it will report its second quarter 2026 financial results on August 4, 2026, according to a Business Wire release.
InfuSystem Holdings Inc. is a leading provider of healthcare services specializing in the supply of durable medical equipment and third-party billing services across the United States and Canada. The company's primary function is to deliver innovative solutions for patients requiring ambulatory infusion pumps for chemotherapy, pain management, and other infusion therapies. Notably, InfuSystem Holdings Inc. supports oncologists and other healthcare stakeholders in managing complex, cost-critical medical treatments outside traditional hospital settings, enhancing patient care and operational efficiencies. It also impacts sectors such as oncology, surgery centers, and home healthcare by offering reliable equipment logistics and comprehensive documentation services. In the financial market, InfuSystem Holdings Inc. represents a critical intersection of healthcare delivery and medical technology, positioning itself as a key player in facilitating advanced medical care with an emphasis on patient comfort and accessibility.
CEO Ms. Carrie A. Lachance B.S.N., M.B.A., R.N. · 461 employees · United States · https://www.infusystem.com